Medicare is willing to reevaluate its coverage of Alzheimer’s drugs in light of a new therapy, called lecanemab, that has shown potentially more promising
Tag - CMS
AUSTIN, Texas – Chiquita Brooks-LaSure, the head of Medicare, said on Thursday that the agency expects to keep covering drugs the Food and Drug Administration
